Solid Biosciences
CHARLESTOWN, Massachusetts, M.D. · Biotechnology, Genetics, Healthcare
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates and neuromuscular and cardiac programs, including SGT-003, for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, AVB-202-TT for th
Key facts
- Headquarters
- CHARLESTOWN, Massachusetts, M.D.
- Employees
- Unknown
- Industries
- Biotechnology, Genetics, Healthcare
- Status
- Public (SLDB)
- Website
- www.solidbio.com
- Company page
Recent activity at Solid Biosciences
- : SEC 8-K (1.01): On March 6, 2026, Solid Biosciences Inc. entered into a Securities Purchase Agreement with certain institutional accredited investors to issue and sell a total of 14,973,257 shares of its common stock at a price of $5.61 per share. Additionally, for investors who prefer, the company will offer pre-funded warrants to purchase 27,807,482 shares at $5.609 each. The Private Placement is scheduled to close on March 9, 2026, contingent upon customary closing conditions. This agreement is strategic for raising capital and expanding operations in the biotech sector.
- : Solid Biosciences Inc. establishes its leadership in precision genetic medicines and outlines key priorities for its advanced clinical-stage pipeline.
- : Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer • Solid Biosciences
- : Solid Biosciences
- : Solid Biosciences Announces Closing Of Acquisition Of Aavantibio And Concurrent $75 Million Private Placement
- : Solid Biosciences Announces Stockholder Approval Of Acquisition Of Aavantibio
- : Solid Biosciences Announces Acquisition Of Aavantibio And Concurrent $75 Million Private Placement
- : Solid Biosciences Inc.
- : Solid Biosciences Inc.
Solid Biosciences funding history
| Date | Round | Amount |
|---|---|---|
| Dec 2022 | Venture | $9.2M |
| Oct 2020 | Venture | $40.0M |
| Jul 2019 | Venture | $60.0M |
Leadership
- Ilan Ganot, Executive Officer, Director
- Robert Huffines, Director
- Adam Koppel, Director
- Sukumar Nagendran, Director
- Rajeev Shah, Director
- Matthew Arnold, Director
- Adam Stone, Director
- Lynne Sullivan, Director
- Martin Freed, Director
- Ian Smith, Director
- Andrey Zarur, Director
- Martin Freed, Director
Verified email and direct lines for Solid Biosciences’s decision-makers are on Fundz. See plans
Solid Biosciences in the news
- Letter to the Duchenne Community - Solid Biosciences (Mar 11, 2026)
- Letter to the Duchenne Community - Solid Biosciences (Jan 13, 2026)
- Letter to the FA Community - Solid Biosciences (Jan 12, 2026)
- Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire (Oct 01, 2026)
- Solid Biosciences’ Gene Therapy SGT-003 Produces Microdystrophin Expression in Patients With DMD - CGTLive® (Feb 18, 2025)
- Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates - GlobeNewswire (Aug 06, 2026)
- Solid Biosciences’ INSPIRE DUCHENNE Study Puts DMD Gene Therapy SGT-003 to the Test - CGTLive® (Jan 20, 2025)
- The Berko Family - Solid Biosciences (Jul 10, 2025)
Companies similar to Solid Biosciences
- Elevation Oncology · Biotechnology, Genetics, Healthcare, Health Care, Therapeutics
- Crispr Therapeutics · Biotechnology, Genetics, Healthcare, Health Care, Therapeutics
- Passage Bio · Biotechnology, Genetics, Healthcare, Health Care, Therapeutics
- EyePoint Pharmaceuticals, Inc. · Biotechnology, Healthcare, Health Care, Therapeutics
- AIM ImmunoTech · Biotechnology, Healthcare, Health Care, Therapeutics
About Solid Biosciences: questions and answers
What does Solid Biosciences do?
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates and neuromuscular and cardiac programs, including SGT-003, for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, AVB-202-TT for th
Where is Solid Biosciences headquartered?
Solid Biosciences is headquartered in CHARLESTOWN, Massachusetts, M.D..
Has Solid Biosciences raised funding?
Yes. Fundz has recorded 3 funding events for Solid Biosciences. The most recent, $9.2M, was in Dec 2022.
What is the latest news on Solid Biosciences?
On Mar 06, 2026, SEC 8-K (1.01): On March 6, 2026, Solid Biosciences Inc. entered into a Securities Purchase Agreement with certain institutional accredited investors to issue and sell a total of 14,973,257 shares of its common stock at a price of $5.61 per share. Additionally, for investors who prefer, the company
Is Solid Biosciences a public company?
Yes. Solid Biosciences is publicly traded under the ticker SLDB.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy